About US
Contact us
-
OTC plant bites Novartis' reputation againThe closed Novartis ($NVS) consumer products plant in Lincoln, NE, that has besmirched the drug giant's reputation and frustratedCEO Joseph Jimenezhas bitten the company again. This time Novartis ack2013/2/1
-
Sanofi nabs FDA approval for Kynamro, despite safety concernsThe FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY)Genzymeunit. But the agency's blessing came with some strings attached: Four post2013/1/31
-
EU enforcers accuse J&J, Novartis of delaying fentanyl genericJohnson & Johnson ($JNJ) and Novartis ($NVS) are the latest pharma companies to feel the ire of EU antitrust regulators.European Commissionofficials have accused the two drugmakers of delaying a g2013/1/31
-
FDA approves Takeda diabetes drug after long waitTakeda Pharmaceutical Company has received approval from the US Food and Drug Administration for Nesina, plus two combinations of the drug, as treatments for type 2 diabetes. Nesina, whose generic na2013/1/30
-
Pfizer's radical R&D cutbacks to continue in 2013Pfizer ($PFE) may be a bit behind schedule, but it's on track to hack its R&D budget to the $6.5 billion-to-$7 billion target laid out in a radical restructuring plan. The company's research spend2013/1/30
-
FDA advisory panel backs limits on painkiller scriptsThe FDA's path through the swamp of painkiller abuse advanced a bit on Friday. An advisory panel backed new controls on hydrocodone drugs, including cough medications and pain pills. The committee re2013/1/29
-
PsiOxus to develop biodefence vaccineThe US Defence Threat Reduction Agency (DTRA) has granted PsiOxus Therapeutics a multi-million dollar contract to be used for research into biodefence vaccine adjuvants with the aim of enhancing thei2013/1/29
-
Xs and Zs become popular in drug namesDrug names starting with an X or a Z may be hard to pronounce but that is really the last thing that drugmakers consider when coming up with new names. They want something that is memorable and evoke2013/1/28
-
Novartis has a win some, lose some day with GleevecNovartis and its cancer drug Gleevec had one of those days that starts off not looking so good and then something comes along to turn things around. It began Friday with the European Medicines Agen2013/1/28
-
New BMS drugs will fill yawning Plavix gap, CEO saysBristol-Myers Squibb's ($BMY) fourth-quarter sales are about as pure an example of generic erosion as we're likely to get. But the company's earnings rose, and newer drugs stepped up, deflecting atte2013/1/25